Chantix Quadruples Smoker’s Chances Of Quitting Successfully

A new drug from Pfizer shows promising results. The results don’t include comparison to nicotine replacement therapy. The results seem to underscore that whatever your method, there’s hope for quitting smoking.

The study lasted one year. Here are some facts from that study:

— 44% of those on Chantix were not smoking at 12 weeks
— 29.5%% of those on Zyban were not smoking at 12 weeks
— 18% of those on a placebo were not smoking at 12 weeks
— 22% of those on Chantix did not smoke from week 9 to 52
— 16% of those on Zyban did not smoke from week 9 to 52
— 8.4% of those on a placebo did not smoke from week 9 to 52

Another study, from the Unversity of Wisconsin included 1,027 volunteers, all of them smokers who wanted to quit. Results were almost the same as the ones above.

The third study involved people in seven countries – 1,900 smokers who wanted to quit. All of them took Chantix for the first 12 weeks, after which 1,236 (65%) were still not smoking. The 1,236 quitters were then divided into two groups: One group continued taking Chantix while the other took a placebo. This continued for another 12 weeks. At the end of the 24-week period:

— 70.5% of those on Chantix were not smoking
— 49.6% of those on a placebo were not smoking